Fig. 5.

(A) Metastasis-free survival in patients with transfusion vs. non-transfusion (4-year MFS rates 72% vs. 87%, p = 0.007, p value calculated by log rank test). (B) Metastasis-free survival in patients with no transfusion, with transfusion only during treatment, or with transfusion before treatment (4-year MFS rates 87%, 78%, and 66%, respectively). (C) Overall survival in patients with no transfusion, with transfusion only during treatment, or with transfusion before treatment (4-year OS rates 88%, 92%, and 72%).